09:26 AM EDT, 09/04/2025 (MT Newswires) -- Bright Minds Biosciences ( DRUG ) said Thursday that preclinical results for its investigational drug BMB-201 in a rat model of vascular headache showed "greater effect sizes" than sumatriptan at several timepoints.

The results showed "statistically significant reductions in facial mechanical allodynia across both male and female cohorts at 1 and 2 hours post-dose" versus vehicle, the company said.

Bright Minds chief executive officer Ian McDonald said the results plus previous efficacy data from a wide range of pain models back "advancing BMB-201 toward clinical development in headache and migraine-related conditions."

The company's shares were up 3.7% in recent Thursday premarket activity.